Vir Hopes To Take On Gilead’s Hepcludex After Positive Early Hepatitis D Results
The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.
The biotech presented preliminary data on chronic hepatitis D from the Phase II SOLSTICE study of tobevibart and elebsiran at the EASL meeting.